



Cdc25A (Phospho-Tyr59) Antibody

#58028

Number: 58028

Amount: 100µg/100µl

Form of Antibody: Rabbit IgG in phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

Storage/Stability: Store at -20°C/1 year

Immunogen: synthetic phosphopeptide corresponding to residues surrounding Tyr59 of human Cdc25A

Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.


Specificity/Sensitivity: Cdc25A (Phospho-Tyr59) antibody detects endogenous levels of Cdc25A only when phosphorylated at Tyrosine59 .

Reactivity: Human


Applications:

Predicted MW: 70KD

WB :1:500~1:1000 IHC:1:50-200



U87/EGFR cells were treated with EGF (100 ng/ml) for 4 h. Immunoblotting analyses were performed with the indicated antibodies without (left panel) or with (right panel) a phosphorylation-blocking peptide.



IHC analyses of human GBM tissues were performed with the indicated antibodies in the presence or absence of specific blocking peptides against Cdc25A pY59. Scale bar, 100 µm.

Background :Many types of human tumour cells overexpress the dual-specificity phosphatase Cdc25A. Cdc25A dephosphorylates cyclin-dependent kinase and regulates the cell cycle. EGFR activation results in c-Src-mediated Cdc25A phosphorylation at Y59, which interacts with nuclear pyruvate kinase M2 (PKM2). In addition, positive correlations at Cdc25A Y59 phosphorylation identified in human glioblastoma specimens, levels of Cdc25A Y59 phosphorylation correlate with grades of glioma malignancy and prognosis [1] .

Reference:[1] Liang J, Cao R, Zhang Y, Xia Y, Zheng Y, Li X, Wang L, Yang W, Lu Z. PKM2 dephosphorylation by Cdc25A promotes the Warburg effect and tumorigenesis. *Nat Commun.* 2016 Aug 3;7:12431. doi: 10.1038/ncomms12431.